124 related articles for article (PubMed ID: 38219288)
1. Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Liu SV; Frohn C; Minasi L; Fernamberg K; Klink AJ; Gajra A; Savill KMZ; Jonna S
Lung Cancer; 2024 Feb; 188():107469. PubMed ID: 38219288
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
3. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
4. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
[TBL] [Abstract][Full Text] [Related]
5. A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.
Chen K; Li W; Xi X; Zhong J
Thorac Cancer; 2022 Nov; 13(21):3063-3067. PubMed ID: 36096509
[TBL] [Abstract][Full Text] [Related]
6. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract][Full Text] [Related]
7. Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugs.
Liu SV
Future Oncol; 2022 Aug; 18(26):2865-2870. PubMed ID: 35876504
[TBL] [Abstract][Full Text] [Related]
8. Successful targeting of the
Wu X; Zhang D; Shi M; Wang F; Li Y; Lin Q
Ann Transl Med; 2021 Oct; 9(19):1507. PubMed ID: 34805369
[TBL] [Abstract][Full Text] [Related]
9. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
[TBL] [Abstract][Full Text] [Related]
10. Plain language summary of publication: new information for the potential role of afatinib in treating people with
Cadranel J
Future Oncol; 2022 Jun; 18(18):2193-2200. PubMed ID: 35400204
[TBL] [Abstract][Full Text] [Related]
11.
Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic Features and Response to Therapy of
Drilon A; Duruisseaux M; Han JY; Ito M; Falcon C; Yang SR; Murciano-Goroff YR; Chen H; Okada M; Molina MA; Wislez M; Brun P; Dupont C; Branden E; Rossi G; Schrock A; Ali S; Gounant V; Magne F; Blum TG; Schram AM; Monnet I; Shih JY; Sabari J; Pérol M; Zhu VW; Nagasaka M; Doebele R; Camidge DR; Arcila M; Ou SI; Moro-Sibilot D; Rosell R; Muscarella LA; Liu SV; Cadranel J
J Clin Oncol; 2021 Sep; 39(25):2791-2802. PubMed ID: 34077268
[TBL] [Abstract][Full Text] [Related]
14. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
[TBL] [Abstract][Full Text] [Related]
16. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.
Agraso S; Lázaro M; Firvida XL; Santomé L; Fernández N; Azpitarte C; Leon L; Garcia C; Hudobro G; Areses MC; Campos B; Quiroga N; García J; Casal J
Cancer Treat Res Commun; 2022; 33():100646. PubMed ID: 36335799
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
18. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Goss GD; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Guclu S; Isla D; Min YJ; Morabito A; Ardizzoni A; Gadgeel SM; Fülöp A; Bühnemann C; Gibson N; Krämer N; Solca F; Cseh A; Ehrnrooth E; Soria JC
JAMA Oncol; 2018 Sep; 4(9):1189-1197. PubMed ID: 29902295
[TBL] [Abstract][Full Text] [Related]
19. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
Pham CP; Nguyen TTH; Do AT; Nguyen TK; Hoang TAT; Le TA; Vuong DTH; Nguyen DNT; Dang VK; Nguyen TO; Pham VL; Nguyen MH; Vo THT; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Nguyen KD; Nguyen HG; Truong CM; Pham TMC; Nguyen TBP
BMC Cancer; 2024 Feb; 24(1):176. PubMed ID: 38317094
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
